



## **Special Interest Group (SIG) on New Medicines (NM) Annual Report 2020**

The Special Interest Groups on New Medicines will provide a platform for the discussion of a wide range of research topics in the pharmaceutical sciences related to drug discovery and development. Importantly, this includes early-stage drug development, with research areas in medicinal chemistry, natural medicines, pharmacology, cell and gene therapies and biologics. Synergy of these topics will corroborate the important role of pharmacists in health care, with new insights in emerging trends in drug discovery and development.

Takuya Kumamoto (Chair)  
Michiho Ito (FG Chair Natural products and Traditional medicines)  
Chun-Wai Mai (FG Chair Pharmacology)  
Juliet Obi (FG Chair Biologics)  
Mathew Cherian (IPS liaison)

The SIG on NM is proud of

Intro to FIP SIG: Drug Delivery & Manufacturing, New Medicines & New Generation of Pharm. Scientists (Jul 12th 2020)

Collaboration with YPG to introduce SIGs to YPG members of FIP, namely the Drug Design and Manufacturing (DDM) SIG, New Generation of Pharmaceutical Scientists (NGPS) SIG, and our New Medicines SIG, respectively.

Goals in 2021:

- Goal #1: Preparation for Brisbane meeting: "Cell and gene therapies as new frontiers in health and medicine" (Organizer: Juliet Obi), and start providing proposal for Cape town meeting.
- Goal #2: Connect with FIP member who chose to be involved with the New Medicines SIG when registering with FIP and organize activities for them to get involved.
- Goal #3: Increase the visibility of the New Medicines SIG by creating an online platform (e.g LinkedIn, Facebook?)